An implant for sleep apnea is one of the few CPAP alternatives. This article compares hypoglossal nerve stimulation and ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

In a report released on January 31, David Low from J.P. Morgan maintained a Buy rating on Resmed (RMD – Research Report), with a price target ...

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

Sleep Apnea Therapy System Market. Key market drivers for Sleep Apnea Therapy System Market include rising prevalence of sleep apnea disorders, growing awa ...

ResMed is an innovation machine. Our ongoing investments of 6% to 7% of revenues ... frontline and gold standard for treating sleep apnea and that these PAP devices -- CPAP APAP bilevel have the ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD ... Robust Continuous Airway Pressure Therapy (CPAP) patient growth assisted by growing awareness on Obstructive Sleep Apnea (OSA), (2) Market share ...